{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:50:35Z","timestamp":1773787835402,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009109","name":"Bayer HealthCare AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejca.2021.05.023","type":"journal-article","created":{"date-parts":[[2021,6,20]],"date-time":"2021-06-20T06:40:39Z","timestamp":1624171239000},"page":"142-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Morland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3684-9909","authenticated-orcid":false,"given":"Didier","family":"Frappaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":false,"given":"Andrew D.J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Kincaide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Schlief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Teufel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart A.","family":"Ploeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan","family":"Cleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea C.","family":"Agostinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynley V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2021.05.023_bib1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/00000478-199807000-00004","article-title":"Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma","volume":"22","author":"Chan","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.ejca.2021.05.023_bib2","first-page":"1900","article-title":"High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas","volume":"6","author":"Eggert","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2021.05.023_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1053\/jpsu.2002.31614","article-title":"Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma","volume":"37","author":"Fakhari","year":"2002","journal-title":"J Pediatr Surg"},{"issue":"12","key":"10.1016\/j.ejca.2021.05.023_bib4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s004320100293","article-title":"Expression of angiogenic factors and tumor progression in human neuroblastoma","volume":"127","author":"Komuro","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.05.023_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00795-004-0273-0","article-title":"Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein","volume":"38","author":"Miyagami","year":"2005","journal-title":"Med Mol Morphol"},{"issue":"4","key":"10.1016\/j.ejca.2021.05.023_bib6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/pbc.24072","article-title":"Vascular endothelial growth factor serum levels in children with newly diagnosed rhabdomyosarcoma","volume":"59","author":"Schiavetti","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2021.05.023_bib7","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1158\/1078-0432.CCR-10-3063","article-title":"FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma","volume":"18","author":"Crose","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ejca.2021.05.023_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077652","article-title":"Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors","volume":"8","author":"Wohrle","year":"2013","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.ejca.2021.05.023_bib9","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2009.26.7252","article-title":"Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease","volume":"28","author":"Paugh","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2021.05.023_bib10","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/0008-5472.CAN-13-1491","article-title":"Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas","volume":"73","author":"Paugh","year":"2013","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2021.05.023_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bpa.12043","article-title":"PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma","volume":"23","author":"Phillips","year":"2013","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2021.05.023_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030313","article-title":"Mesenchymal transition and PDGFRA amplification\/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas","volume":"7","author":"Puget","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejca.2021.05.023_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc799","article-title":"Oncogenic tyrosine kinases and the DNA-damage response","volume":"2","author":"Skorski","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2021.05.023_bib14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","article-title":"Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model","volume":"12","author":"Abou-Elkacem","year":"2013","journal-title":"Mol Cancer Therapeut"},{"issue":"1","key":"10.1016\/j.ejca.2021.05.023_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"issue":"10064","key":"10.1016\/j.ejca.2021.05.023_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2021.05.023_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9863","key":"10.1016\/j.ejca.2021.05.023_bib18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ejca.2021.05.023_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.05.023_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2021.05.023_bib21","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2021.05.023_bib22","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2015.65.1901","article-title":"Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial","volume":"34","author":"Pavlakis","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.023_bib23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2018","journal-title":"Cancer"},{"issue":"9863","key":"10.1016\/j.ejca.2021.05.023_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2021.05.023_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142612","article-title":"Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models","volume":"10","author":"Daudigeos-Dubus","year":"2015","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.ejca.2021.05.023_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"suppl_6","key":"10.1016\/j.ejca.2021.05.023_bib27","first-page":"1559P","article-title":"Evaluation of exposure of regorafenib (REG) and its metabolites in pediatric patients by modeling, simulation, and clinical study","volume":"27","author":"Ploeger","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.05.023_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.ejca.2021.05.023_bib29","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the international neuroblastoma response criteria: a consensus statement from the national Cancer Institute Clinical Trials Planning Meeting","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejca.2021.05.023_bib30","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4155\/bio.14.52","article-title":"Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry","volume":"6","author":"Hafner","year":"2014","journal-title":"Bioanalysis"},{"issue":"12","key":"10.1016\/j.ejca.2021.05.023_bib31","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/bcp.14334","article-title":"Population pharmacokinetics of regorafenib in solid tumors: exposure in clinical practice considering enterohepatic circulation and food intake","volume":"86","author":"Keunecke","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ejca.2021.05.023_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrclinonc.2017.59","article-title":"Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective","volume":"14","author":"Moreno","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.023_bib33","series-title":"Summary of product characteristics","author":"Stivarga","year":"2018"},{"key":"10.1016\/j.ejca.2021.05.023_bib34","series-title":"Full prescribing information","author":"Stivarga","year":"2018"},{"issue":"9","key":"10.1016\/j.ejca.2021.05.023_bib35","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","article-title":"A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors","volume":"18","author":"Mross","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2021.05.023_bib36","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/bjc.2012.153","article-title":"Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study","volume":"106","author":"Strumberg","year":"2012","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2021.05.023_bib37","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.05.023_bib38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2159-8290.CD-20-0487","article-title":"Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain","volume":"11","author":"Grunewald","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.ejca.2021.05.023_bib39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/s41416-019-0389-6","article-title":"Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours","volume":"120","author":"Serrano","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2021.05.023_bib40","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular insight of regorafenib treatment for colorectal cancer","volume":"81","author":"Arai","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ejca.2021.05.023_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14737140.2018.1428092","article-title":"The role of tumor angiogenesis as a therapeutic target in colorectal cancer","volume":"18","author":"Battaglin","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"8","key":"10.1016\/j.ejca.2021.05.023_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27077","article-title":"A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: trial ADVL1211, a report from the Children's Oncology Group","volume":"65","author":"Chuk","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2021.05.023_bib43","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-11-0237","article-title":"Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study","volume":"17","author":"Dubois","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ejca.2021.05.023_bib44","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1002\/cncr.31725","article-title":"A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: a Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315)","volume":"124","author":"Geller","year":"2018","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.ejca.2021.05.023_bib45","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.2012.47.0914","article-title":"Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report","volume":"31","author":"Glade Bender","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2021.05.023_bib46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cam4.598","article-title":"Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies","volume":"5","author":"Reed","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2021.05.023_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","article-title":"Pazopanib in advanced soft tissue sarcomas","volume":"4","author":"Lee","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.ejca.2021.05.023_bib48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2021.05.023_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jth.13551","article-title":"Von Willebrand factor and angiogenesis: basic and applied issues","volume":"15","author":"Randi","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.ejca.2021.05.023_bib50","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","article-title":"Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:33:32Z","timestamp":1760733212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921003324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":50,"alternative-id":["S0959804921003324"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}